BINARY GENOMICS, INC.
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA is a funding opportunity from BINARY GENOMICS, INC., up to 1009228, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
ABSTRACT: Immunotherapies produce remarkable, long-term responses in subsets of patients with non-small cell lung cancer, but unfortunately, most patients do not respond to such treatment. Current biomarkers to predict which patients will benefit have limited accuracy, and decisions to continue or suspend treatment…